JCS/T2D - We are advocates. We learn. We share. We inform.

Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Eli Lilly's Tirzepatide Shows Promise in Phase 3 Trial for Heart Failure and Obesity
FDA Approves Lilly's Tirzepatide for Obesity
GLP-1 Receptor Agonists: A New Hope for Obstructive Sleep Apnea and Chronic Kidney Disease
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
Summary of the Study on Body Size Change and Risk of Type 2 Diabetes and Cardiovascular Disease
The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity
Tune H Pers Awarded for Groundbreaking Obesity and Diabetes Research
Understanding and Addressing the Stigma Faced by People with Type 2 Diabetes and Obesity
Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss